Showing 1701-1710 of 5771 results for "".
- Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 COMET-2 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-phase-3-comet-2-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2480879/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-2 is the first of three trials in t
- Haag-Streit to Host 4th Annuel ‘Slit Lamp Imaging Competition’https://modernod.com/news/haag-streit-launches-4th-slit-lamp-imaging-competition/2480876/Haag-Streit announced the launch the "Slit Lamp Imaging Competition 2022." Following successful competitions held in 2019, 2020 and 2021, the competition gives eye care professionals across the globe an opportunity to showcase their slit lamp imaging skills. Judging criteria will i
- Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol Eye Drops for Night Vision Disturbanceshttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-lynx-1-phase-3-trial-evaluating-nyxol-eye-drops-for-night-vision-disturbances/2480873/Ocuphire Pharma announced positive topline results from the LYNX-1 phase 3 pivotal clinical trial investigating its product candidate Nyxol for night (or dim light) vision disturbances (NVD). More than 650 subjects have now been exposed to Nyxol. NVD is a condition i
- Brim Biotechnology and Ora Announce Partnership to Accelerate Development of Regenerative Peptide Therapy, BRM421, for Dry Eyehttps://modernod.com/news/brim-biotechnology-and-ora-inc-announce-new-partnership-to-accelerate-development-of-regenerative-peptide-therapy-brm421-for-dry-eye-syndrome/2480867/Brim Biotechnology announces it has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). Brim intends to initiate phase 3 clinical studies with Ora’s support later this year.
- Allotex Announces Eye Bank Executive Corrina Patzer Joining Board of Directorshttps://modernod.com/news/allotex-announces-eye-bank-executive-joining-board-of-directors/2480864/Allotex has announced that Corrina Patzer has been appointed to the company’s Board of Directors. "We are excited and honored to welcome Corrina as a new independent director to the Allotex BOD,” said David Muller, CEO of Allotex, “Corrina&rsq
- Alcon Celebrates 75th Anniversaryhttps://modernod.com/news/alcon-celebrates-75-years-of-eye-care-innovation/2480862/Alcon marked the company’s 75th anniversary this week with its "Brilliant History. Brilliant Future." celebration. On May 16, 1947, Alcon Laboratories Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. To
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the ARVO 2022 Annual Meetinghttps://modernod.com/news/meiragtx-presents-clinical-data-on-botaretigene-sparoparvovec-for-the-treatment-of-x-linked-retinitis-pigmentosa-at-the-arvo-2022-annual-meeting/2480844/MeiraGTx Holdings plc announced that additional clinical data from the phase 1/2 trial of botaretigene sparoparvovec for the treatment of x-linked retinitis pigmentosa (XLRP) were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting in Denver, Colo
- EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwanhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-expanded-license-agreement-with-betta-pharmaceuticals-for-eyp-1901-in-china-hong-kong-macau-and-taiwan/2480838/EyePoint Pharmaceuticals announced the execution of a license agreement with Betta Pharmaceuticals to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan. This agreement expands the collaboration between EyePoint and Equinox Sciences, a Bet
- Oxurion Announces Preclinical Data on THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-announces-preclinical-data-on-thr-687-for-the-treatment-of-dme-at-arvo/2480836/Oxurion presented preclinical data from a study evaluating THR-687 for treatment of diabetic macular edema (DME) at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Preclinical data shows THR-687's